Journal Article

Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation

Zheng, Xue, Gong, Yuping, Yan, Tianyou, Deng, Jili, Liu, Xiaoyan, Ye, Wu, Wu, Xia, Zhang, Nanchen

2022

Overview

Background Increasing germline gene mutations have been discovered in haematological malignancies with the development of next-generation sequencing (NGS), which is critical for proper clinical management and long-term follow-up of affected individuals. Tet methylcytosine dioxygenase 2 ( TET2 ) is one of the most common mutations in haematological neoplasms. We aimed to compare the clinical characteristics of patients with germline and somatic TET2 mutations in haematological diseases and to analyse whether germline TET2 mutations have a family aggregation and tumour predisposition. Methods Out of 612 patients who underwent NGS of 34 recurrently mutated genes in haematological diseases, 100 haematological patients with TET2 mutations were selected for further study. Somatic mutations were detected by NGS in bone marrow/peripheral blood genomic DNA (gDNA). Germline TET2 mutations were validated in nail/hair gDNA by Sanger sequencing. Digital data were extracted from the haematology department of the West China Hospital of Sichuan University. TET2 mutation results were analysed by referencing online public databases (COSMIC and ClinVar). Results One hundred patients were studied, including 33 patients with germline and 67 patients with somatic TET2 mutations. For germline TET2 mutations, the variant allele frequency (VAF) was more stable (50.58% [40.5–55], P  < 0.0001), and mutation sites recurrently occurred in three sites, unlike somatic TET2 mutations. Patients with germline TET2 mutations were younger (median age 48, 16–82 years) ( P  = 0.0058) and mainly suffered from myelodysplastic syndromes (MDS) ( n  = 13, 39.4%), while patients with somatic TET2 mutations were mainly affected by acute myeloid leukemia (AML) ( n  = 26, 38.8%) ( P  = 0.0004). Germline TET2 mutation affected the distribution of cell counts in the peripheral blood and bone marrow ( P  < 0.05); it was a poor prognostic factor for MDS patients via univariate analysis (HR = 5.3, 95% CI: 0.89–32.2, P  = 0.0209) but not in multivariate analysis using the Cox regression model ( P  = 0.062). Conclusions Germline TET2 mutation might have a family aggregation, and TET2 may be a predisposition gene for haematological malignancy under the other gene mutations as the second hit. Germline TET2 mutation may play a role in the proportion of blood and bone marrow cells and, most importantly, may be an adverse factor for MDS patients.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Acute myeloid leukemia / Analysis / Biomedical and Life Sciences / Biomedicine / Cancer Research / Care and treatment / Diagnosis / DNA sequencing / Gene mutations / Germline TET2 mutation / Health aspects / Health Promotion and Disease Prevention / Medicine/Public Health / Myelodysplastic syndromes / Nucleotide sequencing / Oncology / Research Article / Risk factors / Somatic TET2 mutation / Surgical Oncology